keynote-045 – pembrolizumab as second-line treatment in urothelial carcinoma
Published 7 years ago • 202 plays • Length 1:09Download video MP4
Download video MP3
Similar videos
-
2:35
keynote-361 and -045: pembrolizumab monotherapy in urothelial carcinoma
-
1:23
how effective is pembrolizumab in cisplatin-ineligible bladder cancer? results from keynote-052
-
2:05
pembrolizumab as second-line therapy for advanced urothelial carcinoma
-
4:00
overview of urothelial carcinoma treatment landscape – the promise of immunotherapy
-
1:19
dr. bellmunt shares keynote-045 data for pembrolizumab versus chemotherapy in bladder cancer
-
2:57
highlights in bladder canceres: keynote-045 keynote-052 dr. fabio schutz
-
1:18
dr. plimack on keynote-045 trial for pembrolizumab in urothelial carcinoma
-
2:18
ema restrict pembrolizumab/atezolizumab usage in urothelial cancer
-
1:48
what does the 2-year follow-up tell us about the use of pembrolizumab for advanced bladder cancer?
-
2:43
pembrolizumab: defining standards of care in urothelial cancer
-
3:45
fierce-22 trial: vofatamab with pembrolizumab for urothelial carcinoma
-
0:51
impact of the keynote-045 study comparing pembrolizumab and chemotherapy in bladder cancer
-
2:25
keynote-224: second-line pembrolizumab for advanced hepatocellular carcinoma
-
3:51
is pembrolizumab alone sufficient to treat bladder cancer?
-
4:34
optimising treatment for advanced urothelial cancer: combination, maintenance or sequencing?
-
0:58
significance of keynote-045 trial of pembrolizumab vs chemotherapy in urothelial carcinoma
-
1:33
ambassador: pembrolizumab for locally advanced bladder cancer
-
1:09
dr. plimack on frontline pembrolizumab for urothelial carcinoma
-
0:57
dr. petrylak on the keynote-045 trial for urothelial carcinoma